HFSA 2019 Annual Scientific Meeting

HFSA 2019 Annual Scientific Meeting

Regular price
$40.00
Sale price
$40.00
Regular price
Sold out
Unit price
per 

[


 

The Heart Failure Society of America has released the 23rd HFSA Annual Scientific Meeting Advance Program. Taking place September 13-16, 2019, the HFSA Annual Scientific Meeting offers heart failure professionals the opportunity to advance their understanding and knowledge of heart failure with a robust, multidisciplinary program.


Topics/Speaker:



    1. PM 1 – Excellence in Translational Science

    2. SAT 1 – Mitral Regurgitation in Heart Failure 2019 Challenges and Opportunities

    3. SAT 2 – Cardiovascular, Metabolic, and Renal Outcomes in Multi-Morbid Heart Failure Patients with Type 2 Diabetes

    4. SAT 3 – Improving Outcomes in Your HF Patients with Evidence-Based Treatment of Hyperkalemia

    5. PLENARY – Independence from Heart Failure Awareness, Empathy and Activism

    6. SESSION 1 – Acute Cardiogenic Shock to Recovery STEMI, Myocarditis, and Acute Insults

    7. SESSION 2 – Great Debates and Current Controversies Across the Atlantic

    8. SESSION 3 – Ten Simple Tips How to Prevent HF

    9. SESSION 4 – Prognosis and Treatments for Ambulatory Advanced HF

    10. SESSION 5 – General Cardiology vs Community and Academic HF – Let’s Learn from Each Other

    11. SESSION 6 – Ten Simple Tips Management of Complexities in Cardiogenic Shock

    12. SESSION 7 – Rapid Fire Abstracts for Original Investigations

    13. SESSION 8 – Challenges in Managing Adult Congenital Heart Disease PH, RV Failure, Arrhythmia

    14. SESSION 9 – Change is Inevitable Impact of Nursing and Allied Health Amongst the Medical Circulatory Support World

    15. SESSION 10 – FDA Special Session Focusing on Patient in Clinical Research and Drug Development

    16. SAT 4 – Symptoms are the Tip of the Iceberg Navigating Management of Congestion in Heart Failure

    17. SAT 5 – Team Based Approach to Combined Medical and Surgical Management of Advanced Heart Failure Optimal Use and Impact of Mechanical Circulatory Support

    18. SESSION 11 – Ten Simple Tips Identifying the Ever-Elusive Volume Overload in the Clinic

    19. SESSION 12 – 2019 Update on Clinical Trials for Emerging HF Drugs and Device Therapies

    20. SESSION 13 – Defining RV Failure Pathophysiology and Clinical Perspectives

    21. SESSION 14 – JNC Investigator Award Basic Science & Clinical

    22. SESSION 15 – Nursing Investigator Award Research & Clinical1

    23. SESSION 16 – Ten Simple Tips How to Best Implement Technologies to Assist in HF Care and Reduce Readmissions

    24. SESSION 17 – Systemic Pathway Dysregulation in HFpEF How Mechanisms Enlighten Clinical Approaches

    25. Session 18 – HF in End-Stage Kidney Disease A Multidisciplinary Approach to an Underestimated Problem1

    26. SESSION 19 – Contemporary Dilemmas in LVAD Therapy

    27. SESSION 20 – Fundamental skills for AHFTC Training

    28. SESSION 22 – Systems of care in Cardiogenic Shock

    29. 2018-2019 Top Ten Trials, News & Publication in HF

    30. SESSION 26 – Payer Mandates for Formal Shared Decision-Making How do I Meet Coverage Decision Mandates

    31. SESSION 23 – Translational Omics in Heart Failure Finally Getting Clinical

    32. SESSION 25 – Lessons Learned 100 Years from HF Nurses

    33. SESSION 27 – International Session Global Challenges and Best Practices in Acute HF

    34. SESSION 28 – How to Diagnose and Manage Inflammatory Cardiomyopathies Myocarditis Foundation

    35. Diet, Nutrition & Cardiac Function – From Beside to Bench & Back Again

    36. SESSION 30 – Clinical Conundrums Pharmacotherapy for HFrEF Case-Based Debates

    37. SESSION 31 – How to Engage Patient-Caregiver Dyads in Managing HF

    38. SAT 6 – Reducing Cardiovascular and Renal Risk with SGLT2 Inhibitors Exploring Evidence

    39. SAT 7 – Brave New World of ATTR Cardiac Amyloidosis Avoiding Pitfalls in Diagnosis and Treatment

    40. SESSION 34 – Ten Simple Tips Cardiac Amyloidosis – No Longer an Academic Exercise, Now a Treatable Pandemic

    41. Controversies in Acute Cardio-Renal Syndrome – Discussion & Debates on Fluid Wars

    42. SESSION 35 – How to Manage Cardiovascular Complications during Pregnancy

    43. Clinical Conundrums – Managing AFib & Device Therapies in HF – Case-Based Debates

    44. SESSION 37 – Advocacy Committee The Multidimensional Challenge of Drug Pricing and Preapprovals

    45. SESSION 39 – The Spectrum of Care for Patients with Genetic Cardiomyopathies

    46. SESSION 38 – Late Breaking Clinical Trials

    47. SESSION 40 – Ten Simple Tips Management of Patients with Diabetes and HF

    48. SESSION 41 – Functional Mitral Regurgitation An Update on Treatment Strategies

    49. SESSION 42 – Barriers to Implementation of New Therapies

    50. SESSION 53 – Late Breaking Clinical Trials and Insights with Angiotensin Receptor Neprilysn Inhibitors

    51. SESSION 43 – Ten Simple Tips How to Best Treat Volume Overload in Acute HF

    52. SESSION 44 – New Insights in Cardio-Oncology

    53. SESSION 45 – Understanding the Heart-Brain Connection New Insights in Cognitive Impairment and Sleep-Disordered Breathing

    54. SESSION 46 – The New Heart Transplantation Allocation

    55. SESSION 47 – Pharmacist-Driven Transition of Care and Optimization Clinics

    56. SESSION 54 – HF Awareness in African Americans

    57. SESSION 48 – HYDE PARK

    58. SESSION 49 – Addressing the Recovered Ejection Fraction Is It Still Heart Failure

    59. SESSION 50 – Ten Simple Tips Managing Patients Across the Spectrum of Pulmonary Hypertension

    60. SESSION 51 – The Psychosocial Assessment of the Advanced HF Patient

    61. SESSION 52 – Learning Health Systems, Real World Evidence and HF Hype or Reality






    Reviews


    There are no reviews yet.






    Only logged in customers who have purchased this product may leave a review.








    ]